Back to top
more

Veru (VERU)

(Delayed Data from NSDQ)

$0.73 USD

0.73
610,215

-0.01 (-1.32%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $0.74 +0.01 (0.89%) 6:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Veru (VERU) delivered earnings and revenue surprises of -16.67% and 12.97%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Capricor (CAPR) delivered earnings and revenue surprises of -9.38% and 11.95%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Baxter (BAX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures and a more stable supply chain.

What Makes Veru (VERU) a New Buy Stock

by Zacks Equity Research

Veru (VERU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Veru Inc. (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?

by Zacks Equity Research

Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.

Charles River (CRL) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

The service business within Charles River (CRL) RMS is expected to have witnessed growth in the fourth quarter, banking on small molecule revenue increase across several geographic regions.

Veru Inc. (VERU) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Veru Inc. (VERU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Verano Holdings Corp. (VRNOF) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of 0% and 0.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Veru Inc. (VERU) delivered earnings and revenue surprises of 35% and 59.26%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 0% and 3.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Vapotherm (VAPO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Vapotherm (VAPO) delivered earnings and revenue surprises of 23.68% and 4.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Lantheus Holdings (LNTH) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 15.79% and 4.97%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Blue Water (BWV) Up on Acquisition of 6 FDA-Approved Drugs

by Zacks Equity Research

Blue Water (BWV) soars 62% after declaring its deal to purchase six FDA-approved products for $8.5 million. The agreement will help expand the company's portfolio into cardiology and pain management.

Veru Inc. (VERU) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Veru Inc. (VERU) delivered earnings and revenue surprises of -33.33% and 66.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Veru (VERU) This Earnings Season?

by Zacks Equity Research

Veru (VERU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Veru Inc. (VERU) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Veru Inc. (VERU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

fuboTV (FUBO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

fuboTV's (FUBO) first-quarter results are expected to reflect growth in paid subscribers and viewing supported by increased advertiser demand on the company's sports live TV streaming platform.

Zynex Inc. (ZYXI) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 300% and 6.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Down -51.21% in 4 Weeks, Here's Why You Should You Buy the Dip in Veru Inc. (VERU)

by Zacks Equity Research

Veru Inc. (VERU) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Veru Inc. (VERU) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Veru Inc. (VERU) delivered earnings and revenue surprises of -21.05% and 50.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Veru Inc. (VERU) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Veru Inc. (VERU) delivered earnings and revenue surprises of -75.86% and 77.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Meridian Bioscience (VIVO) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 33.33% and 2.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Fortress Biotech (FBIO) delivered earnings and revenue surprises of 7.41% and 13.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?